Multiple streams of late-stage data and regulatory movement are reinforcing the commercial and clinical pull of TROP2-directed ADC strategies. An ASCO-abstract snapshot described sacituzumab tirumotecan (sacituzumab tirumotecan, sac-TMT) paired with Keytruda producing a 65% reduction in risk of disease progression versus Keytruda alone in a first-line non-small cell lung cancer subset, with response rates over 70% reported for the combination. The same period also included continued emphasis on the broader TROP2 class, with ADC-focused study efforts in lung and other tumor types. The sequence of trial data and subsequent FDA actions on Datroway suggests developers are racing to establish first-line ADC benchmark positions by pairing with backbone immunotherapies. For biotech stakeholders, the signal is less about incremental response and more about endpoint separation—especially where ADC combinations are demonstrating consistency across discontinuation rates, response depth, and time-to-event metrics.